News

Indianapolis Business Journal2h
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Novo Nordisk hopes to see US Wegovy sales recover soon
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
BioSpace2d
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Pharmaceutical Technology on MSN7d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...